To assess the efficacy of ICIs (dual anti-PD-1 and anti-CTLA-4 monoclonal antibodies) in a murine model of dMMR CRC, C57BL/6 mice bearing MC38 tumors were treated with 250 μg of anti-PD-1 and anti-CTLA-4 monoclonal antibodies every 3 days for a total of eight doses, while monitoring tumor growth (Figure 1A). The gene discussed is CTLA4; the disease is colorectal carcinoma.